NCT00441610已完成1 期
An Extension Trial to a Phase I Dose Escalation Study of LBQ707 (Gimatecan) Administered Orally 5 Consecutive Days to Japanese Patients With Advanced Solid Tumor
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 4
- 试验地点
- 1
- 主要终点
- Anti-tumor activity assessed by RECIST criteria
研究概览
简要总结
CLBQ707A1101 assesses the tolerability, safety, efficacy and pharmacokinetics of gimatecan in Japanese patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
Gimatecan
Experimental
干预措施: Gimatecan (Drug)
结局指标
主要结局
Anti-tumor activity assessed by RECIST criteria
时间窗: 2.8 years
Safety and tolerability assessed by Adverse Events
时间窗: 2.8 years
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Phase I Dose Escalation Study of LBQ707 (Gimatecan) Administered Orally Twice Per Week to Japanese Patients With Advanced Solid TumorsAdvanced Solid TumorsNCT00487058Novartis28
已完成
1 期
A Dose Escalation of Gimatecan Administered Orally to Japanese Patients With Advanced Solid Tumor.Advanced Solid TumorsNCT00410358Novartis Pharmaceuticals19
Unknown
1 期
A Clinical Study of Gimatecan in Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer or Primary Peritoneal CancerOvarian Epithelial CancerFallopian Tube CancerPrimary Peritoneal CancerNCT04029909Lee's Pharmaceutical Limited12
已完成
1 期
Dose-escalation Study of Gimatecan Administered in Two Different Schedules in Adult Patients With Advanced Solid TumorsSolid TumorsNCT00420485Novartis Pharmaceuticals120
已完成
1 期
Phase I Study of Gimatecan in Patients With Myelodysplastic SyndromesMyelodysplastic SyndromesMDSNCT00493571M.D. Anderson Cancer Center16